Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Invested Capital: 2009-2025

Historic Invested Capital for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Sep 2025 value amounting to $965.5 million.

  • Madrigal Pharmaceuticals' Invested Capital rose 7.97% to $965.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $965.5 million, marking a year-over-year increase of 7.97%. This contributed to the annual value of $872.0 million for FY2024, which is 67.42% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Invested Capital of $965.5 million as of Q3 2025, which was up 18.56% from $814.4 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Invested Capital ranged from a high of $973.7 million in Q2 2024 and a low of $78.5 million during Q3 2022.
  • In the last 3 years, Madrigal Pharmaceuticals' Invested Capital had a median value of $828.6 million in 2025 and averaged $682.4 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 66.57% in 2022, then soared by 422.52% in 2024.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Invested Capital stood at $196.1 million in 2021, then spiked by 36.18% to $267.1 million in 2022, then skyrocketed by 95.01% to $520.8 million in 2023, then soared by 67.42% to $872.0 million in 2024, then increased by 7.97% to $965.5 million in 2025.
  • Its Invested Capital was $965.5 million in Q3 2025, compared to $814.4 million in Q2 2025 and $828.6 million in Q1 2025.